We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Evaluate Relative Bioavailability of PA32540 (Asa/Omeprazole), Its Aspirin Component, and Ecotrin® in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00632086
Recruitment Status : Completed
First Posted : March 10, 2008
Last Update Posted : March 10, 2008
Information provided by:

Study Description
Brief Summary:
Study to determine a single dose bioavailablity of PA32540 is similar to EC aspirin 325 mg with respect to salicylic acid.

Condition or disease Intervention/treatment Phase
Healthy Drug: PA32540 Drug: aspirin component of PA32540 Drug: Ecotrin Phase 1

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: A Phase 1, Open-Label, Randomized, 3-Way Crossover Study to Evaluate the Relative Bioavailability of a Single Oral Dose of Aspirin Administered as PA32540 (Aspirin/Omeprazole) or as the Aspirin Component of PA32540 or as Ecotrin® 325 mg in Healthy Volunteers
Study Start Date : February 2008
Primary Completion Date : February 2008
Study Completion Date : February 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: 1
Single oral dose of 325 mg aspirin administered as PA32540
Drug: PA32540
Experimental: 2
aspirin core
Drug: aspirin component of PA32540
The 325 mg aspirin component of PA32540
Active Comparator: 3
Drug: Ecotrin
325 mg Ecotrin

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Standard for PK
  • Ages 18-55 years old
  • Males and females

Exclusion Criteria:

  • Standard for PK
More Information

Responsible Party: Connie Powers, Pozen
ClinicalTrials.gov Identifier: NCT00632086     History of Changes
Other Study ID Numbers: PA32540-104
First Posted: March 10, 2008    Key Record Dates
Last Update Posted: March 10, 2008
Last Verified: February 2008

Keywords provided by POZEN:

Additional relevant MeSH terms:
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors